RGNX investors have opportunity to lead REGENXBIO Inc. securities fraud lawsuit with the Schall Law Firm. GlobeNewswire | Schall Law Today at 8:30am PDT LOS ANGELES, March 19, 2026 (GLOBE NEWSWIRE) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2026. Wallowa also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach Wallowa through the firm's website at www.schallfirm.com, or by email at [email protected]. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Regenxbio's statements to investors about product candidate RGX-111 were overwhelmingly positive while it concealed negative data on its efficacy and safety. The Company then revealed an intraventricular CNS tumor was discovered in a participant treated as part of a RGX-111 study. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Regenxbio, investors suffered damages. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. The Schall Law Firm This is a paid placement. For further inquiries, please contact GlobeNewswire directly.

Regenxbio, Solid report data with Duchenne gene therapies. This week saw both Regenxbio and Solid Bio report new data with their gene therapy candidates for Duchenne muscular dystrophy (DMD), vying to join Sarepta's Elevidys on the market. Regenxbio gave an update on the phase 2/3 AFFINITY DUCHENNE trial of its RGX-202, reporting interim results that showed it was well tolerated, achieved robust expression of microdystrophin to replace the mutated dystrophin protein in DMD, and led to early functional improvements in ambulatory DMD patients aged one and over. The data, from seven subjects in the study treated with the target dose of RGX-202, showed that their motor function 12 months later - measured using the North Star Ambulatory Assessment (NSAA) scale and timed function tests - was improved compared to matched external natural history comparisons and predictive modelling. The results also showed that patients demonstrated cardiac stability at one year post-treatment as measured by MRI endpoints, an important finding as DMD causes progressive cardiac muscle degeneration (cardiomyopathy). The company is now expecting to report pivotal data from the study in the second quarter of this year, and said it will ask for a meeting with the FDA to look at possible pathways toward filing RGX-202 for accelerated approval while it runs an ongoing confirmatory study. Solid Bio, meanwhile, reported this week that its SGT-003 candidate had also achieved strong expression of microdystrophin, along with improvements in muscle integrity, including stabilisation and improvement in cardiac function in its phase 1/2 INSPIRE DUCHENNE trial. For now, the investigators remain blinded to the motor function data in the study, which has now enrolled 40 subjects. Solid Bio said it is hoping to schedule meetings with the FDA in the first half of this year to seek guidance on accelerated approval, and indicated that it already has an agreement with the agency on the design of a phase 3 trial that will be called IMPACT DUCHENNE and is due to start dosing patients before the end of this month. Both companies are hoping to provide an alternative one-shot treatment to Elevidys, which was launched in 2023, but ran into trouble last year after three fatalities were reported in non-ambulatory DMD recipients, leading to a pause in distribution. The fatalities, linked to liver toxicity, eventually resulted in Elevidys' label being restricted to ambulatory patients only, but did not stop the product knocking on the door of blockbuster status last year, with sales of $899 million. Regenxbio and Solid Bio have both pointed to the safety profile of their gene therapies, saying there was no evidence of liver injury in their trial updates. The two studies were presented at the 2026 Muscular Dystrophy Association (MDA) annual meeting earlier this week. 13 March, 2026